Q-omics provides the consensus-scored LINC02870 profile across patient tissues and cancer cell-line models. LINC02870 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02870 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LINC02870 RNA expression shows 14,434 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where LINC02870 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02870 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02870 survival associations across molecular data types. LINC02870 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02870 RNA expression–survival associations across cancer types. High LINC02870 expression shows unfavorable associations in KIRC, UVM, KIRP, COAD, LGG and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02870 RNA expression.
This table summarizes LINC02870 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02870. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02870 shows higher tumor expression in HNSC, COAD, LUSC, LUAD, THCA and BRCA. The HNSC box plot shows higher LINC02870 RNA expression in tumor versus normal tissue (log2 FC = +1.330, t-test p < 0.001).
This table shows molecular features associated with LINC02870 in patient tissues and cancer cell lines. In patient samples, LINC02870 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
